Advances in the diagnosis, pathophysiology and treatment of chronic non-specific ulcerative colitis;Avances en el diagnóstico, fisiopatología y tratamiento de la colitis ulcerativa crónica inespecífica

Revista de Gastroenterologia de Mexico

Volumn 78, Issue , 2013, Pages 65-67

  Gonzalez Altamirano J ^a   Paz Delgadillo, J ^a   Bosques Padilla, F ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL THERAPY; COLON TUMOR; CONFERENCE PAPER; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; ULCERATIVE COLITIS;

BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION;

MLCS; MLOWN;

EID: 84903507488     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rgmx.2013.06.033     Document Type: Article

References (15)

1. Ohman, L., Dahlen, R., Isaksson, S., et al. Serum IL-17A in newly diagnosed treatment-naïve ulcerative colitis patients reflects disease severity and predicts the course of disease. [abstract] Gastroenterology 144:5 Suppl. 1 (2013), S–S35.
2. Yamamoto-Furusho, J.K., Cedillo-Suarez, W., Campos Gonzalez, C., The ultrasensitive c reactive protein (Hs CRP) is a relapse marker in patients with ulcerative colitis and correlates with the IL-6 gene expression in colonic mucosa. [abstract] Gastroenterology, 144(5 Suppl. 1), 2013, S417.
3. Dionne, S., Adelson, B.A., Piccirillo, C., et al. Influence of NOD2 genotype on the modulatory effect of vitamin D on NOD2 and TLRinduced cytokine responses in Crohn's disease. [abstract] Gastroenterology, 144(5 Suppl. 1), 2013, S7.
4. Ananthakrishnan, A.N., Normalization of vitamin D status is associated with reduced risk of surgery and hospitalization in inflammatory bowel disease: a prospective study [abstract]. Gastroenterology, 144(5 Suppl. 1), 2013, S1.
5. Gregory, A.P., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488 (2012), 508–511.
6. Billiet, T., Cleynen, I., Ballet, V., et al. Primary response to infliximab in Crohn's disease is associated with the Tnfrsf1a Rs1800693 gene polymorphism [abstract]. Gastroenterology 144:5 Suppl. 1 (2013), S467–S468.
7. Adedokun, O.J., Xu, Z., Marano, C.W., et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately to severely active ulcerative colitis: results from phase 2/3 induction and maintenance studies [abstract]. Gastroenterology 144:5 Suppl. 1 (2013), S228–S229.
8. Mostafa, N.M., Eckert, D., Pradhan, R.J., et al. Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis [abstract]. Gastroenterology 144:5 Suppl. 1 (2013), S225–S226.
9. Stobaugh, D.J., Deepak, P., Ehrenpreis, E.D., Risk of melanoma and non-melanoma skin cancers with pharmacotherapy among inflammatory bowel disease patients: an analysis of the food and drug administration adverse event reporting system [abstract]. Gastroenterology, 144(5 Suppl. 1), 2013, S415.
10. Ananthakrishnan, A.N., McGinley, E.L., Weekend hospitalizations are associated with increased post-operative complications following urgent surgery for ulcerative colitis [abstract]. Gastroenterology, 144(5 Suppl. 1), 2013, S617.
11. Vermeire, S., O'Byrne, S., Williams, M., et al. Differentiation between etrolizumab (Rhumab Beta7) and placebo in the eucalyptus phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to-severely active ulcerative colitis [abstract]. Gastroenterology, 144(5 Suppl. 1), 2013, S3.
12. Knittel, T., Befrits, R., Lofberg, R., et al. Sustained clinical response and remission achieved in moderately severe ulcerative colitis patients by local application of the TLR-9 agonist DIMS0150 [abstract]. Gastroenterology 144:5 Suppl. 1 (2013), S20–S21.
13. Musch, E., Lutfi, T., von Stein, P., et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 19 (2013), 283–292.
14. Khomeriki, S.G., Knyazev, O., Influence of mesenchymal stem cells on morphological reparation of intestinal mucosa in experiments and in patients with ulcerative colitis [abstract]. Gastroenterology, 144(5 Suppl. 1), 2013, S463.
15. Sala, E., Anselmo, A., Arena, V., et al. Mesenchymal stem cells ameliorate experimental colitis by secretion of TNF-alfa stimulated gene/protein 6 and not by gut-homing [abstract]. Gastroenterology, 144(5 Suppl. 1), 2013, S465.